Vivoryon Therapeutics NV represents core values of innovation, collaboration, and commitment to addressing unmet medical needs. The company is dedicated to developing innovative small molecule therapeutics for challenging diseases, particularly in the field of age-related diseases. By fostering strong collaborations and partnerships, Vivoryon Therapeutics aims to accelerate the discovery and development of groundbreaking treatments. With a focus on precision medicine, the company seeks to improve patient outcomes and quality of life. Vivoryon Therapeutics NV is committed to advancing scientific knowledge and delivering effective therapies to patients worldwide.

Vivoryon Therapeutics NV is primarily present in Europe, specifically in Germany and the Netherlands.

Vivoryon Therapeutics NV has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in 2020, raising funds to further advance its innovative therapeutic programs. Vivoryon also received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its lead product candidate, QSI-001, a potential treatment for Alzheimer's disease. Moreover, Vivoryon has initiated multiple clinical trials, including Phase 1b/2a studies for QSI-001, demonstrating its commitment to advancing novel therapies for serious diseases. These milestones highlight Vivoryon Therapeutics NV's progress in developing transformative treatments and underline its dedication to improving patients' lives.

Vivoryon Therapeutics NV is a biotech company that specializes in developing small molecule therapeutics for the treatment of neurodegenerative diseases. Founded in 2017, Vivoryon Therapeutics NV is based in Germany and focuses on targeting the ubiquitin-proteasome system and the unfolded protein response to tackle diseases like Alzheimer's and Parkinson's. The company's innovative platform has attracted numerous partnerships and collaborations with renowned academic institutions and pharmaceutical companies. With a strong commitment to research and development, Vivoryon Therapeutics NV aims to improve patients' lives by advancing novel therapies for neurodegenerative disorders.

The main competitors of Vivoryon Therapeutics NV in the market are other pharmaceutical and biotechnology companies that specialize in developing therapeutics for various diseases and conditions. These competitors include large multinational corporations as well as smaller research-focused organizations. It is important for Vivoryon Therapeutics NV to stay competitive in the market by continuously innovating and developing their drug candidates to address unmet medical needs.

Vivoryon Therapeutics NV is primarily active in the healthcare and biotechnology industries.

The business model of Vivoryon Therapeutics NV is focused on developing small molecule drugs for treating age-related diseases. Vivoryon Therapeutics NV utilizes a unique approach called "drug surveillance technology" to identify specific enzymes involved in aging processes and develop novel drugs to target them. By targeting enzymes implicated in diseases like Alzheimer's and Parkinson's, Vivoryon Therapeutics NV aims to modify disease progression and improve patient outcomes. Through strategic partnerships, collaborations, and clinical trials, the company aims to bring innovative therapies to market and revolutionize the treatment landscape for age-related diseases.

Az Vivoryon Therapeutics P/E mutatója -1,98.

Az Vivoryon Therapeutics KUV 0.

Az AlleAktien Minőségi Score Vivoryon Therapeutics esetében 4/10.

A Vivoryon Therapeutics esetében jelenleg nem számítható ki az árbevétel.

A(z) várt Vivoryon Therapeutics nyereség -26,68 Mió. EUR.

Vivoryon Therapeutics NV is a company specializing in the development of therapeutics for the treatment of age-related diseases. The company uses the latest technologies and research findings to discover and develop innovative compounds that can effectively combat age-related diseases. The business model of Vivoryon Therapeutics is based on the development and commercialization of drugs for the treatment of Alzheimer's disease, Parkinson's disease, ALS, and other age-related disorders. The company follows a rational drug discovery approach that focuses on the identification of molecules that specifically interact with disease processes. An important pillar of Vivoryon Therapeutics' business model is collaboration with partners and customers. The company works closely with pharmaceutical and biotech companies to license or sell its technologies and products. By collaborating with existing industry players, Vivoryon Therapeutics can leverage synergies and optimize the distribution of its products. Vivoryon Therapeutics has divided its business fields into several segments, each focused on the development of different products and technologies. The main segments include: 1. Discovery of drug candidates: The company uses its proprietary "Functional Tau Pipeline Technology" platform to discover and develop drug candidates that target disease processes specifically. 2. Drug development: Vivoryon Therapeutics employs innovative screening technologies and optimizes its drug candidates to enhance the efficacy and tolerability of the medications. The company also works on the development of combination therapies and personalized medicines. 3. Commercialization: The company aims to bring its products to the global market and become a leading provider of therapeutics for the treatment of age-related diseases worldwide. Vivoryon Therapeutics follows a strategy of direct sales but also collaborates with distribution partners to bring its products to various regional markets. The business model of Vivoryon Therapeutics is based on the development of innovative therapeutics for the treatment of age-related diseases, relying on the discovery and development of drug candidates and innovative screening technologies. The company works closely with other industry players to leverage synergies and optimize the distribution of its products. Vivoryon Therapeutics follows a strategy of direct sales but also collaborates with distribution partners to bring its products to various regional markets.

A(z) Vivoryon Therapeutics évente alkalommal oszt ki 0 EUR összegű osztalékot.

A Vivoryon Therapeutics esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Vivoryon Therapeutics ISIN kódja: NL00150002Q7.

A Vivoryon Therapeutics WKN-je A2QJV6.

Az Vivoryon Therapeutics tőzsdei rövidítése VVY.AS.

Az elmúlt 12 hónapban a(z) Vivoryon Therapeutics osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) Vivoryon Therapeutics várhatóan 0 EUR összegű osztalékot fog fizetni.

A(z) Vivoryon Therapeutics jelenlegi osztalékhozama .

A(z) Vivoryon Therapeutics negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A Vivoryon Therapeutics az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 EUR összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) Vivoryon Therapeutics a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Vivoryon Therapeutics által 2024. 09. 21.-án/én fizetett 0 EUR összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 09. 21.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 09. 21. időpontban történt.

2023 évben a Vivoryon Therapeutics 0 EUR összegű osztalékot fizetett ki.

Az Vivoryon Therapeutics osztalékait EUR fizeti ki.